Patrick Wen, MDEnriched profile
Director, Neuro-Oncology Division, Brigham and Women's Hospital; Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Professor of Neurology, Harvard Medical School · Dana-Farber Cancer Institute
Overview
Updated 14 Jul 2026
Patrick Y. Wen is Director, Neuro-Oncology Division, Brigham and Women's Hospital at Dana-Farber Cancer Institute / Brigham and Women's Hospital / Harvard Medical School (Boston, MA). The public record shows 1,915 publications with 89,244 citations (h-index 146), centered on Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Cancer, Hypoxia, and Metabolism. It also documents an investigator role on 27 registered clinical trials, 4 NIH-funded awards (1990–2015).
- Most recent indexed publication: 2026 · Nature medicine
- Top research focus: Glioma Diagnosis and Treatment
- 27 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 58 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 674.
Clinical & industrytrials, payments and federal funding
Not shown. No U.S. clinical registration on file.
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 27 registered studies on ClinicalTrials.gov. The most recent:
- Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Sponsor: Alliance for Clinical Trials in Oncology
InvestigatorPhase 3RecruitingNCT07215910 - Surgical Nivolumab And Ipilimumab For Recurrent GBM
Sponsor: Patrick Wen, MD
InvestigatorPhase 1Active, not recruitingNCT04606316 - VB-111 in Surgically Accessible Recurrent/Progressive GBM
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 2TerminatedNCT04406272
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
Updated 14 Jul 2026
4 NIH research awards on record, funded 1990–2015 per NIH RePORTER. The latest:
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited worksby citation count (OpenAlex)
- 01Malignant Gliomas in Adults4,244 citations2008
- 02
- 03
- 04
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
60 Fenwood Road, 1st Floor, Hale Building for Transformative Medicine, Boston, MA 02115
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
Editorial & leadership rolesjournal and society appointments
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pmc.ncbi.nlm.nih.gov ↗
- Executive Editor
Neuro-Oncology (Oxford Academic / Society for Neuro-Oncology journal)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →academic.oup.com ↗ - Former President
Society for Neuro-Oncology (SNO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Secondary affiliationsappointments beyond the home institution
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biospace.com ↗
- Scientific Advisor
Candel Therapeutics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →candeltx.com ↗ - Course Director
Harvard Medical School Professional, Corporate, and Continuing Education
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →learn.hms.harvard.edu ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/patrick-wen-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Patrick-Y-Wen-38800436
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- Other
curetoday.com/view/how-fda-approved-modeyso-works-to-treat-glioma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →curetoday.com ↗ - Other
onclive.com/view/fda-approval-insights-dordaviprone-in-h3k27m-mutated-diffuse-midline-glioma-with-patrick-y-wen-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - X / Twitter
x.com/DanaFarberNews/status/1970178782364303773
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Nikhil Munshi, MD
Dana-Farber Cancer Institute
- 1,801
- publications
- 152
- h-index
- 8
- trials
Geoffrey Shapiro, MD
Dana-Farber Cancer Institute
- 2,055
- publications
- 116
- h-index
- 24
- trials
Irene Ghobrial, MD
Dana-Farber Cancer Institute
- 1,124
- publications
- 101
- h-index
- 16
- trials
Patrick Ott, MD
Dana-Farber Cancer Institute
- 616
- publications
- 82
- h-index
- 8
- trials